Clinical Trial Update: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) [Phase 2]

View source ↗

Summary

Phase 2 trial update for autologous CD30.CAR-T cells in relapsed/refractory Hodgkin lymphoma (CHARIOT) is ongoing (Phase 2, active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease Pediatric
• Hodgkin Disease Recurrent
• Hodgkin Disease Refractory
• Hodgkin Lymphoma

Drugs mentioned

• CD30 CAR-T

Snippet

Sponsor: Tessa Therapeutics | Conditions: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING